Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

886

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

DRUG: Enfortumab vedotin
DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]
[object Object]